Presentations

Presentations

Sep 22, 2022

CRISPR Therapeutics Corporate Presentation

Jun 21, 2022

Innovation Day Presentation

Jun 12, 2022

EHA 2022 (Exa-cel)

Jun 11, 2022

2022 EHA Oral Presentation (CTX130 COLBALT-LYM)

May 05, 2022

2021 Annual Report

Apr 21, 2022

2020 Annual Report

Apr 20, 2022

2021 Compensation Report

Apr 20, 2022

2021 Statutory Financial Statements

Apr 20, 2022

2021 Consolidated Audit Report

Apr 11, 2022

2022 AACR Annual Meeting

Mar 22, 2022

2021 PFIC Annual Information Statement

Nov 08, 2021

Jun 11, 2021

EHA 2021 Virtual Congress (TDT)

Jun 11, 2021

EHA 2021 Virtual Congress (SCD)

Apr 10, 2021

2021 AACR Annual Meeting

Mar 09, 2021

2020 PFIC Annual Information Statement

Mar 04, 2021

CRISPR Therapeutics Corporate Presentation

Feb 01, 2021

CRISPR Therapeutics Corporate Presentation

Jan 04, 2021

CRISPR Therapeutics Corporate Presentation

Dec 09, 2020

Phase 1/2 CTX001™ Investor Update Presentation

Dec 06, 2020

2020 ASH Meeting and Exposition Presentation

Oct 21, 2020

Phase 1 CARBON Top-Line Data Presentation

Jul 27, 2020

Jul 27, 2020

2019 Annual Report

Jun 17, 2020

2020 AACR II Virtual Meeting Poster: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors

Jun 16, 2020

2020 AACR II Virtual Meeting Poster: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro

Jun 15, 2020

2020 AACR II Virtual Meeting Poster: Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors

Jun 14, 2020

2020 AACR II Virtual Meeting Poster: Targeting T cell lymphomas with CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T cells

Jun 12, 2020

2020 European Hematology Association (EHA) Congress Presentation

May 11, 2020

2020 ASGCT Annual Meeting Poster: Insertion of Short Double-Stranded Oligonucleotides Using CRISPR/Cas9 as a Therapeutic Approach for Glycogen Storage Disease Type 1a

May 11, 2020

2020 ASGCT Annual Meeting Poster: Dual Guide CRISPR/Cas9 Editing of the CCR5 Gene Provides Complete Protection Against HIV in Humanized Mouse Models

May 11, 2020

2020 ASGCT Annual Meeting Poster: Multiplexing of up to 10 gene edits using CRISPR/Cas9 generate CAR-T cells with improved function

Apr 07, 2020

2019 PFIC Annual Information Statement

Apr 02, 2020

CRISPR Therapeutics Corporate Presentation

Mar 18, 2020

CRISPR Therapeutics Corporate Presentation

Nov 19, 2019

CRISPR Therapeutics Data Update Call Presentation

Nov 08, 2019

2019 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: Single-cell RNA sequencing and functional assessment of healthy donor- and cancer patient-derived T and CAR-T cells

Sep 17, 2019

2019 European Association for the Study of Diabetes (EASD) Presentation

May 01, 2019

2019 ASGCT Annual Meeting Poster: CRISPR/Cas9 Gene Editing to Produce Multiple Allogeneic CAR-T Cell Candidates Showing Consistently High Potency, Durability, Lack of Alloreactivity, and Ability to Overcome Immune Suppression

Apr 02, 2019

2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Targeting multiple solid tumor types with anti-CD70 allogeneic CAR-T cells

Apr 01, 2019

2019 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR/Cas9 Gene-edited CAR-T Cells Targeting CD33 Show Potent Preclinical Activity Against AML Cells

Dec 01, 2018

2018 Annual Meeting of The American Society of Hematology (ASH) Poster: Preclinical Development of CTX120, an Allogeneic CAR-T Cell Product Candidate Targeting BCMA

Nov 09, 2018

2018 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T Cell Function

May 15, 2018

2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9

Apr 16, 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen

Apr 16, 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.